These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15568207)

  • 1. Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness--one larger vs two smaller pivotal studies.
    Shun Z; Chi E; Durrleman S; Fisher L
    Stat Med; 2005 Jun; 24(11):1619-37; discussion 1639-56. PubMed ID: 15568207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility probability in clinical trials.
    Shao J; Chow SC
    Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More efficient clinical trials through use of scientific model-based statistical tests.
    Jonsson EN; Sheiner LB
    Clin Pharmacol Ther; 2002 Dec; 72(6):603-14. PubMed ID: 12496742
    [No Abstract]   [Full Text] [Related]  

  • 7. Some drop-the-loser designs for monitoring multiple doses.
    Joshua Chen YH; Demets DL; Gordon Lan KK
    Stat Med; 2010 Jul; 29(17):1793-807. PubMed ID: 20658548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods for active extension trials.
    Hu Z; Follmann D
    Stat Med; 2007 May; 26(12):2433-48. PubMed ID: 17066400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pathways for evaluating potential acute stroke therapies.
    Fisher M; Cheung K; Howard G; Warach S
    Int J Stroke; 2006 May; 1(2):52-8. PubMed ID: 18706045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs.
    Reed SD; Anstrom KJ; Seils DM; Califf RM; Schulman KA
    Health Aff (Millwood); 2008; 27(5):w360-70. PubMed ID: 18682441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on the FDA draft guidance on adaptive designs.
    Wittes J
    J Biopharm Stat; 2010 Nov; 20(6):1166-70. PubMed ID: 21058112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.